The full name of chronic lymphocytic leukemia is called chronic lymphocytic leukemia, and the differences in patients’ conditions, physical fitness, and treatment effects will affect the survival period, which ranges from 1.5 years to more than 10 years. 1. For low-risk patients, through active and standardized treatment, the survival period is usually longer, reaching more than 10 years. 2. For intermediate-risk patients, the survival period may be shorter, around 5 years. 3. For high-risk patients, the survival period is shorter, about 1.5~5 years. Chronic lymphocytic leukemia is a malignant tumor disease, due to the different conditions of each patient, different physical condition, different treatment effects, there is a large gap in the survival time, can not be generalized. Drugs include nitrogen mustard phenylbutyrate, ibrutinib and so on. Patients should actively cooperate with doctors to do standardized treatment in order to prolong the survival time.